How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process?
Pharmaceutical companies are now also engaging the public themselves in an attempt to build trust in their products.
Pharmaceuticals
-
Read more: How are COVID-19 Vaccine Manufacturers Building Trust in the FDA’s Approval Process? -
Read more: Fortifying the US Pharmaceutical Supply Chain Fortifying the US Pharmaceutical Supply Chain
Reducing dependency on any single nation must be a federal priority, but it can be accomplished only with industry stakeholder buy-in.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Selections feature topics ranging from political pressures facing the FDA, to the financial incentive structure for antibiotic development.
-
Read more: Experts Question FDA Approval of Remdesivir for COVID-19 Experts Question FDA Approval of Remdesivir for COVID-19
Experts are calling into question the recent decision of the U.S. Food and Drug Administration to approve remdesivir for the treatment of COVID-19.
-
Read more: Neurodiversity and Psychedelics Decriminalization Neurodiversity and Psychedelics Decriminalization
A focus on furthering neurodiversity could allow the psychedelics decriminalization movement to gain broader public support.
-
Read more: Psychedelics Helped Me Reclaim My Life and Push to Change Drug Laws Psychedelics Helped Me Reclaim My Life and Push to Change Drug Laws
I am not the usual protagonist you’d imagine as an advocate for psychedelics. But I had a psychedelic experience that changed my life.
-
Read more: Psychedelics and America: A Digital Symposium Psychedelics and America: A Digital Symposium
This digital symposium for the Petrie-Flom Center’s Bill of Health blog explores the role psychedelics may play in America’s future.
-
Read more: COVID-19’s Impact on Clinical Trials: Meeting Participants Where They Are COVID-19’s Impact on Clinical Trials: Meeting Participants Where They Are
In light of COVID-19, a site and sponsor’s ability to flex to “meet the participant where they are” will be critical to the conduct of clinical trials.
-
Read more: Duplicate Discounts Threaten the 340B Program During COVID-19 Duplicate Discounts Threaten the 340B Program During COVID-19
The 340B program, which provides discount drugs to safety-net hospitals, faces an uncertain future due to increased demand spurred by the COVID-19 pandemic.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on pharma, health law, and policy issues from August 2020.
